Opinion|Videos|November 18, 2026

Patient Factors and Access Barriers in Extensive-Stage SCLC

Small cell lung cancer still lacks predictive biomarkers, so comorbidities, performance status, and caregiver support drive treatment choices, while financial and logistical barriers threaten access to the newest options.

This episode, "Patient Factors and Access Barriers in Extensive-Stage SCLC," features the panel exploring what actually drives treatment choice in the absence of predictive biomarkers.

With no validated predictive biomarkers yet available for small cell lung cancer, this episode explores what does drive treatment selection today: patient characteristics, comorbidities, and performance status. The panel notes that transcriptional subtyping research is underway and may eventually inform therapy choice, but for now, clinical judgment and conversations with patients about what they can tolerate remain the primary guide, particularly once patients reach the maintenance phase and some understandably feel too worn down by induction chemotherapy to continue.

Age and comprehensive geriatric assessment feature prominently in this discussion, since a majority of small cell lung cancer patients are older, often over 70. The panel describes coordinating closely with primary care to assess whether a patient has the support system needed before proceeding with additional lines of therapy, given that prior biomarker-driven approaches in this population have largely returned negative results, leaving performance status, comorbidities, and caregiver availability as the practical decision points that matter most.

The episode closes on access and financial barriers, which the panel describes in stark terms. Patients often emerge from chemoradiation or induction chemotherapy in a diminished state, frequently unable to return to work, right at the moment they may be offered some of the most expensive treatments in the field. This creates substantial financial risk for both patients and practices. The panel also raises transportation vulnerability, insurance status following job loss, and the availability of patient assistance programs, grants, and foundations as critical, and often overlooked, components of making innovative therapies genuinely accessible rather than theoretically available.

Our next episode, "The Future of SCLC: Bispecifics, ADCs, and Biomarkers," looks ahead to the bispecific agents and antibody-drug conjugates the panel expects to define what comes next.


Related to this article